China-based Jo2006incare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) is set to advance its Category 1 chemical drug, JKN2403, into clinical trials for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD), following approval from the National Medical Products Administration (NMPA).
JKN2403: A Novel COPD Treatment with Promising Phase I Results
JKN2403 is an in-licensed oral COPD drug that has shown promising results in Phase I trials conducted in Europe. The drug works by effectively preventing the production of inflammatory mediators in COPD by inhibiting the activity of prolyl endopeptidase (PREP), a key enzyme in the disease’s pathophysiology. This mechanism of action is significant as it controls the acute exacerbation of COPD, a critical aspect of the condition’s management.
Unmet Need for PREP Inhibitors Globally
The approval for JKN2403 to proceed to clinical trials is notable as there is currently no prolyl endopeptidase (PREP) inhibitor approved anywhere in the world. This represents a significant opportunity to fill a gap in the treatment options available for COPD patients, who often suffer from a lack of effective therapeutic alternatives.-Fineline Info & Tech
